Biogen Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B |
| TECFIDERA | — | $679.7M | $967.1M | $1.01B | $1.44B | $1.95B | $3.84B | $4.43B |
| Interferon (AVONEX+PLEGRIDY combined) | — | — | — | — | — | — | — | $2.10B |
| AVONEX | — | $695.5M | $707.5M | $811.0M | $973.5M | $1.21B | $1.49B | — |
| PLEGRIDY | — | $250.1M | $260.5M | $294.7M | $331.9M | $357.4M | $385.6M | — |
| TYSABRI | — | $1.67B | $1.72B | $1.88B | $2.03B | $2.06B | $1.95B | $1.89B |
| FAMPYRA | — | $1.4M | $71.7M | $90.5M | $96.6M | $105.2M | $103.1M | $97.1M |
| ZINBRYTA | — | — | — | — | — | — | — | — |
| VUMERITY | — | $746.8M | $628.0M | $576.3M | $553.4M | $410.4M | $64.3M | $5.5M |
| ELOCTATE | — | — | — | — | — | — | — | — |
| ALPROLIX | — | — | — | — | — | — | — | — |
| FUMADERM | — | — | — | — | $8.2M | $11.0M | $12.2M | $15.2M |
| SPINRAZA | — | $1.55B | $1.57B | $1.74B | $1.79B | $1.91B | $2.05B | $2.10B |
| ADUHELM | — | — | — | — | $4.8M | $3.0M | $0 | — |
| BENEPALI | — | $453.2M | $479.1M | $438.8M | $441.0M | $498.3M | $481.6M | $486.2M |
| IMRALDI | — | $190.2M | $213.1M | $222.1M | $224.5M | $233.4M | $216.3M | $184.0M |
| FLIXABI | — | $52.6M | $63.2M | $77.4M | $81.3M | $99.4M | $97.9M | $68.1M |
| BYOOVIZ | — | $32.4M | $36.6M | $31.7M | $4.3M | — | — | — |
| TOFIDENCE | — | $700.0K | $1.1M | — | — | — | — | — |
| QALSODY | — | $86.9M | $32.4M | $5.9M | — | — | — | — |
| SKYCLARYS | — | $520.5M | $382.5M | $55.9M | — | — | — | — |
| ZURZUVAE | — | $195.1M | $72.2M | — | — | — | — | — |
| FUMADERM and ADUHELM (combined) | — | $2.1M | $10.3M | — | — | — | — | — |
| Other Product Revenue | — | — | — | $11.8M | — | — | — | — |
| Revenue from anti-CD20 therapeutic programs | — | $1.86B | $1.75B | $1.69B | $1.70B | $1.66B | $1.98B | $2.29B |
| Alzheimer's collaboration revenue | — | $177.7M | $59.9M | — | — | — | — | — |
| Contract manufacturing, royalty and other revenue | — | $732.9M | $652.6M | $899.3M | $485.1M | $476.3M | $774.6M | $707.7M |
| Cost of Revenue | — | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B |
| Gross Profit | — | $7.49B | $7.37B | $7.30B | $7.90B | $8.87B | $11.64B | $12.42B |
| Gross Margin | — | 75.7% | 76.1% | 74.2% | 77.6% | 80.8% | 86.6% | 86.4% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B | $2.37B |
| Operating Income | — | $1.82B | $2.16B | $1.54B | $3.84B | $2.84B | $4.55B | $7.04B |
| Operating Margin | — | 18.4% | 22.3% | 15.7% | 37.7% | 25.9% | 33.8% | 49.0% |
| Interest Expense | — | $267.5M | $250.3M | $246.9M | $246.6M | $253.6M | $222.5M | $187.4M |
| Pretax Income | — | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B | $5.05B | $7.13B |
| Income Tax Expense | — | $263.6M | $273.8M | $135.3M | $632.8M | $52.5M | $992.3M | $1.16B |
| Net Income | — | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B |
| Net Margin | — | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% |
| EPS (Basic) | — | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 |
| EPS (Diluted) | — | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 |
| Shares Outstanding (Basic) | 146.8M | 146.5M | 145.6M | 144.7M | 145.3M | 149.1M | 160.9M | 187.1M |
| Shares Outstanding (Diluted) | 146.8M | 147.1M | 145.9M | 145.6M | 146.0M | 149.6M | 161.3M | 187.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |